Latest Commercial Agreements News

Lunnon Metals reports robust high-grade gold assay results from its Lady Herial deposit, underpinning a low-risk open pit development opportunity within the Kambalda Gold & Nickel Project.

Vulcan Energy has obtained the crucial permit to build and operate its Central Lithium Plant in Frankfurt, marking a significant milestone in Europe's push for sustainable, domestic lithium production to support electric vehicle battery manufacturing.

Boab Metals has extended its option to acquire full ownership of the Sorby Hills Project to the end of 2025, while locking in critical commercial agreements and environmental approvals that pave the way for a final investment decision.

Hazer Group and First Graphene have signed a non-binding MOU to explore innovative applications for Hazer’s proprietary graphite, aiming to capitalize on rising global demand amid supply constraints.

First Graphene Limited reveals significant progress in commercialising its PureGRAPH graphene technology, highlighting expanding global partnerships and a robust sales pipeline valued over A$10 million.

Singular Health Group reported a $6.38 million loss for FY2025 while securing a pivotal $1.3 million commercial agreement with US-based Provider Network Solutions to deploy its 3DICOM software. The company also completed a major cloud migration of its platform, positioning itself for growth in the US healthcare market.

Adveritas Limited reported a robust 89% increase in revenue to $7.84 million for FY25, driven by expanding customer contracts and product enhancements, while reducing its net loss by 39%. The company raised $8.5 million to fuel US expansion and new verticals.

Aquirian Limited reported a 12.6% revenue increase to $26.07 million for FY25 but posted a $3.41 million statutory loss amid ramp-up costs and impairments. The company is advancing its Energetics and Technology divisions, including the Wubin Emulsion Facility and Collar Keeper® System.

Genetic Signatures Limited reported a 63% revenue surge to $15.9 million in FY25, driven by strong Australian sales and progress in EMEA, while navigating a $20.1 million net loss and a strategic pivot towards partnerships for automated diagnostics.

Artrya Limited has secured FDA 510(k) clearance for its Salix Coronary Plaque module, enabling near real-time detection of high-risk coronary artery plaque and opening a lucrative U.S. market opportunity with a $950 reimbursement per scan.

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Carnaby Resources has completed its acquisition of the Trekelano mining leases, advancing exploration and integration efforts within its Greater Duchess Copper Gold Project.